Liver cancer
2L+ advanced HCC1
Liver cancer
2L+ advanced HCC1
2L+, second line or later; HCC, hepatocellular carcinoma; IV, intravenous; QxW, every x weeks.
1. Opdivo® (nivolumab). Hong Kong Prescribing Information; Hong Kong: Bristol-Myers Squibb; 2023.